Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Anticancer Bioscience Ltd.

Headquarters: Chengdu, China
Year Founded: 2016
Status: Private

BioCentury | Oct 15, 2021
Product Development

Oct. 14 Quick Takes: BeiGene, BMS spar as pharma seeks end to Abraxane deal

Plus: Culture, Anticancer, Rejuvenate, Regeneron and more
BioCentury | Jul 14, 2021
Management Tracks

BeiGene’s Liang joins Tessera as president, CFO; plus Vera, Entasis, Iterion and Anticancer

Howard Liang joined gene writing company Tessera Therapeutics Inc. as president and CFO. Liang was most recently CFO and chief strategy officer at BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160), leading the
BioCentury | Jun 14, 2021
Emerging Company Profile

Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers

Emerging Company Profile: Chengdu-based ACB joins a growing wave of next-gen synthetic lethality companies 
BioCentury | May 15, 2021
Emerging Company Profile

Median seed, A round sizes have more than doubled since 2017 

2021 is turning out to be a bumper year, in particular for start-ups with new modalities
BioCentury | Apr 3, 2021
Management Tracks

Biotech CEOs in China: a broadening talent pool

It’s no longer only MNCs. CEOs from domestic biotechs, academia and investment communities a growing source of China CEOs
Items per page:
1 - 6 of 6